EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Treatment Options in Spinal Muscular Atrophy: A Pragmatic Approach for Clinicians

Sithara Ramdas, Maryam Oskoui, Laurent Servais

Drugs · 2024

DOI: 10.1007/s40265-024-02051-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drugs, 2024. Verfasst von Sithara Ramdas und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, MDUK Oxford Neuromuscular Centre and NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: Muscular Atrophy, Spinal. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 119 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Spinal muscular atrophy (SMA) is a rare neurodegenerative neuromuscular disorder with a wide phenotypic spectrum of severity. SMA was previously life limiting for patients with the most severe phenotype and resulted in progressive disability for those with less severe phenotypes. This has changed dramatically in the past few years with the approvals of three disease-modifying treatments. We review the evidence supporting the use of currently approved SMA treatments (nusinersen, onasemnogene abeparvovec, and risdiplam), focusing on mechanisms of action, side effect profiles, published clinical trial data, health economics, and pending questions. Whilst there is robust data from clinical trials of efficacy and side effect profile for individual drugs in select SMA populations, there are no comparative head-to-head clinical trials. This presents a challenge for clinicians who need to make recommendations on the best treatment option for an individual patient and we hope to provide a pragmatic approach for clinicians across each SMA profile based on current evidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Atrophy, SpinalHumansOligonucleotidesPyrimidinesAzo CompoundsBiological ProductsRecombinant Fusion Proteins

Substanzen

RisdiplamnusinersenOligonucleotidesPyrimidinesZolgensmaAzo CompoundsBiological ProductsRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Paediatrics, MDUK Oxford Neuromuscular Centre and NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
  • Department of Paediatric Neurology, John Radcliffe Hospital, Oxford, UK.
  • Departments of Pediatrics and Neurology and Neurosurgery, McGill University, Montreal, Canada.
  • Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Canada.
  • Department of Paediatrics, MDUK Oxford Neuromuscular Centre and NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK. Laurent.servais@paediatrics.ox.ac.uk.
  • Division of Child Neurology, Department of Pediatrics, Centre de Référence des Maladies Neuromusculaires, University Hospital Liège and University of Liège, Liège, Belgium. Laurent.servais@paediatrics.ox.ac.uk.

Zitieren

APA

Ramdas, S., Oskoui, M., & Servais, L. (2024). Treatment Options in Spinal Muscular Atrophy: A Pragmatic Approach for Clinicians. Drugs. https://doi.org/10.1007/s40265-024-02051-2

Vancouver

Ramdas S, Oskoui M, Servais L. Treatment Options in Spinal Muscular Atrophy: A Pragmatic Approach for Clinicians. Drugs. 2024. doi:10.1007/s40265-024-02051-2

BibTeX
@article{Ramdas2024,
  author = {Ramdas, Sithara and Oskoui, Maryam and Servais, Laurent},
  title = {Treatment Options in Spinal Muscular Atrophy: A Pragmatic Approach for Clinicians},
  journal = {Drugs},
  year = {2024},
  doi = {10.1007/s40265-024-02051-2}
}
Kostenlos starten →